Vontobel Financial Products GmbH (F13783) Quote

When you learn how to keep score get back to me. Skenes left two runners on base and they were not ghost runners. LMAO.

Yes!!!!!!!!!!


Letssss go


Regards

OMG, here comes the news and a NICKEL

And there you have it, yet more false statements on the crowds by the magas

https://twitter.com/WUTangKids/status/1789661928278630603?s=19

DNU, correct.

he said in 2019 that he would wipe our shareholders, said the same in 2008. at least watt said he does not lose sleep over it. but catman repeated wiping out shareholders as if that is all he thinks about on how to. you wonder why would the previous admin put him as fhfa director? if they really ca

You’ve been corrected 100 times on your made up 5% number. There is no control arm with the same inclusion/exclusion criteria as the treatment arm that the company will divulge. They won’t release that data.

The 5% is from ALL GBM patients including those with biopsy only and those w

Holy crap....is that recent. One does not normally see that many different colors in the same event at the same time. I believe that is a rare occurrence.
At least in most of the states.

Wonder if this will break the $1.00 price ?

Tesla pulls back from supercharger network. https://finance.yahoo.com/news/elon-musk-backtracks-on-supercharger-network-halt-says-more-chargers-coming-170947263.html

For some reason, Musk seems to like contradicting himself.

And that statement was true for the filing period ending 12/31/23... After that, they filed an amendment to the corporate charter with the RS included.

3M—Today, it seems like they have greatly cut back on research… The actual numbers don’t show that. These are 3M’s R&D expenses as a percentage of sales for 2018-2023:

2023 5.6%
2022 5.4%
2021 5.6%
2020 5.8%
2019 5.9%
2018 5.6%

RNAZ FDA Fast track status For terminally ill cancer patients, The holy grail of RNA cancer research

I was out, on and off, all night through morning. It was the most vivid for me around 2 AM but nothing as spectacular as some of the shots I've seen, including the one Drifter posted here..

UPDATED!!! ASM Slide 38 "Multi-Level & Cross Functional Engagements"

most people do NOT understand how deeply embedded Lebby is throughout the entire Photonics Industry Food Chain, what this slide is telling investors that when the "Big Silicon Foundries" LWLG is working with (see SNN

wonder if Fortitude Advisors know about this 5 yr. work history anomaly:

imagizer.imageshack.com/v2/1600x1200q70/923/9kQUHd.jpg

SMH - yikes folks

MOO deceitful

The article Synopsis Photonics Solutions posted on LinkedIn was from the PIC Magazine article by Michael Lebby here

https://www.linkedin.com/posts/synopsysphotonicsolutions_article-by-michael-lebby-ceo-lightwave-activity-7181893534705201153-QcJ2/

Synopsys reposted anoth

I know you are on a roll here posting about Adam and the stock. In all the posts I have not seen anything regarding you contacting Adam and voicing your opinion. Email him all your complaints about him and the company. Ask him about all the items you have issues with. Let it all out with him and let

Finalllllyyy.

Jester, I'm looking forward to MA approval in the UK because I think it will open the door to all the other news that's been waiting on this first APPROVAL! And that is the franchises/partnerships that will bring in the big money from Pharmas and other companies. Once retailers/institutions see BP t

RNAZ The Holy Grail Of Cancer Research The Stars and Stripes", "Old Glory", Star-Spangled Banner" RnA Breakthrough for terminally ill cancer patients

I think DCVax + poly iclc will be the placebo

DCvax has always been a great placebo as proven by the P3. Just so darn expensive for doing what a placebo does.

Another losing bet LOL!!!

I expect them to get signed contracts or at least MOUs this year within other industries though. I don’t think they have to have reached metric tons by then. They just need to demonstrate the quality and attributes of the silk thru sent samples. Hopefully they are sending samples out post haste.